Meta AnalysisID 686
外用壬二酸治疗皮肤疾病和美容护肤的有效性
CRD42020220648
The overall objective of the systematic review will be to evaluate the effectiveness and safety of topical azelaic acid compared with placebo and active treatments for anti-ageing and the dermatological conditions of ros
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 686
- Evidence Id
- 9244
- Core Evidence Id
- 9244
- Source Meta Analysis Id
- 665
- Herb2 Meta Analysis Id
- HBMA000665
- Crd Id
- CRD42020220648
- Title
- The effectiveness of topical azelaic acid for dermatological conditions and cosmetic skin care
- Review Question
- The overall objective of the systematic review will be to evaluate the effectiveness and safety of topical azelaic acid compared with placebo and active treatments for anti-ageing and the dermatological conditions of rosacea, melasma, hyperpigmentation, and acne. The specific questions that this systematic review will seek to answer is: 1. What high quality evidence exists to address this topic? 2. What dosages, and dosage forms of azelaic acid may be most effective? 3. What duration of azelaic acid treatment may be most effective? 4. What is the safety and tolerability of azelaic acid in the general population, and also in pregnant and breastfeeding women if reported in the included studies?
- Study Type Included
- Only randomised controlled trials (RCTs) will be eligible for inclusion. There will be no limits on the size of the sample or the duration of follow-up. However, the intervention must have been applied for at least six weeks or more in order to have had an adequate time for effectiveness to be ascertained. Cross-over RCTs will not be eligible for inclusion unless data are reported at cross-over. Randomised controlled trials that include intra-individual studies (e.g. where only one half of the face receives treatment, and the other half receives vehicle) will also be eligible for inclusion.
- Condition Being Studied
- Skin conditions: anti-ageing and the dermatological conditions of rosacea, melasma, hyperpigmentation, and acne
- Participant
- Inclusion criteria: Studies of adolescents and/or adults (12 years of age or older) who are healthy will be included in the review. Studies that have a participant mean or median age of 12 years will not be eligible for inclusion. If, however, studies are mostly in adolescents and/or adults, but happen to include a small number of individuals less than 12 years of age (i.e. <5% of the study sample), we will consider this study to be eligible. Exclusion criteria: Studies of participants taking any other medications for minor or serious illnesses will be excluded.
- Animal
- Human Disease Modelled
- Intervention
- Studies that evaluate the effectiveness of topical azelaic acid in any form (i.e. gel, foam, or cream) that can be applied to the face, will be eligible for inclusion. Any dose of azelaic acid will be considered. Studies that evaluate combination therapy of azelaic acid with other treatments versus vehicle will not be included. If, however, a study compares an active treatment in combination with azelaic acid versus that same active treatment without azelaic acid we will include these studies as they are essentially comparing the efficacy of the addition of azelaic acid. This includes concomitant interventions such as sunscreen which may be given to both intervention and vehicle groups. Studies that evaluate the face and neck will not be included unless data are reported separately for the face.
- Comparator Control
- Studies that compare topical azelaic acid with a topical vehicle (or no treatment or a placebo) will be eligible for inclusion for all indications. In addition, studies that compare two different doses of azelaic acid, or different durations will be included. In addition, active comparators will be included including acids, topical retinoids, antibiotics, other topical treatments, other oral treatments, and procedures (a full list of these for each indication are specified in the full protocol) Studies that compare AA with any of the above combined comparator treatments will also be included.
- Main Outcome
- To be eligible for inclusion in the review, the studies will have to assess changes in rosacea (e.g. redness/erythema), hyperpigmentation, melasma, and acne as well as measures of anti-ageing, including improvements in photoaging, wrinkles, and dull skin. Any measure or scoring system may be used to evaluate effectiveness – this may be done by the investigator or by the study participant. Adverse event data, including local skin reactions such as burning, pruritus, erythema, exfoliation, pain, dryness, discolouration, or irritation will be collected where reported. Any serious adverse events will also be collected where reported. Where studies report several outcomes or measures to assess effectiveness, we will focus on the primary outcome(s) as stated by the study authors and/or the outcomes/measures that are most commonly reported amongst the included studies in order to facilitate a comparison. Measures of effect Means and standard deviations will be collected for continuous outcomes and used to estimate study-specific and pooled mean differences with 95% confidence intervals (CIs). Numerators and denominators will be collected for dichotomous outcomes, with Mantel-Haenszel (M-H) risk ratios (RRs) and 95% CIs used to summarize effect sizes. If the scales/tools used to assess the outcomes differ between the studies, we will compute study-level standardised mean differences (SMD) between comparison groups with 95% CIs.
- Outcome Measure
- Additional Outcome
- None Measures of effect Not applicable
- Study Method
- Intervention, Systematic review
- Keyword
- Cosmetics; Dicarboxylic Acids; Humans; Skin Care; azelaic acid
- Contact
- Sarah King [email protected]
- Organisational Affiliation
- on behalf of Dermatica https://www.dermatica.co.uk/
- Funding Source
- Funded by Dermatica (in-house research)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-11-13
- Registration Date
- 2020-11-17
- Anticipated Start Date
- 2020-11-16
- Anticipated Completion Date
- 2021-02-28
- Title Cn
- 外用壬二酸治疗皮肤疾病和美容护肤的有效性
- Title En
- The effectiveness of topical azelaic acid for dermatological conditions and cosmetic skin care
- Bilingual Status
- complete